FDA Approves Adjuvant Atezolizumab for Certain Colon Cancers
(MedPage Today) -- The FDA on Thursday approved intravenous atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III mismatch repair-deficient (dMMR) colon cancer in patients 2 years...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.